SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2018
Commission File Number 001-38370
CollPlant Holdings Ltd.
(Exact name of registrant as specified in its charter)
3 Sapir Street, Weizmann Science Park
Ness Ziona 74140, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ¨
Attached hereto as Exhibit 99.1 and incorporated by reference herein is a press release issued by the Registrant entitled “CollPlant Announces Closing of Global Licensing and Commercialization Agreement with United Therapeutics for 3D Bioprinting of Solid-Organ Scaffolds for Human Transplants”.
|99.1||Press Release, dated November 12, 2018|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|COLLPLANT HOLDINGS LTD.|
|Date: November 13, 2018||By:||/s/ Eran Rotem|
|Title:||Deputy CEO and Chief Financial Officer|